Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 368 Neoplasms 324 Neoplasm Metastasis 287 Leukemia, Myeloid, Acute 279 Breast Neoplasms 275 Colorectal Neoplasms 233 Melanoma 197 Ovarian Neoplasms 189 Recurrence 187 Multiple Myeloma 177 Prostatic Neoplasms 156 Pancreatic Neoplasms 156 Lung Neoplasms 156 Squamous Cell Carcinoma of Head and Neck 148 Glioblastoma 145 Lymphoma, Non-Hodgkin 143 Triple Negative Breast Neoplasms 118 Myelodysplastic Syndromes 114 Carcinoma, Renal Cell 111 Stomach Neoplasms 110 Precursor Cell Lymphoblastic Leukemia-Lymphoma 105 Glioma 105 Advanced Solid Tumors 104 Lymphoma 103 Lymphoma, Large B-Cell, Diffuse 102 Brain Neoplasms 102 Lymphoma, B-Cell 98 Carcinoma, Hepatocellular 94 Endometrial Neoplasms 92 Lymphoma, Follicular 90

Interventions

vistusertib 1 olaparib 1 durvalumab 1 danvatirsen 1 adavosertib 1 AZD4547 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Muscle Invasive Bladder Cancer × 1 year × Clear all

NCT02546661 2025-12-29

BISCAY

AstraZeneca

Phase 1 Active not recruiting

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡